Predictive Biomarkers and Personalized Medicine BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

Purpose: Despite initial sensitivity to chemotherapy, ovarian cancers (OVCA) often develop drug resistance, which limits patient survival. Using specimens and/or genomic data from 289 patients and a panel of cancer cell lines, we explored genome-wide expression changes that underlie the evolution of OVCA chemoresistance and characterized the BCL2 antagonist of cell death (BAD) apoptosis pathway as a determinant of chemosensitivity and patient survival. Experimental Design: Serial OVCA cell cisplatin treatments were performed in parallel with measurements of genome-wide expression changes. Pathway analysis was carried out on genes associated with increasing cisplatin resistance (EC50). BAD-pathway expression and BAD protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemosensitivity and/or clinical outcome and as therapeutic targets. Results: Induced in vitro OVCA cisplatin resistance was associated with BAD-pathway expression (P < 0.001). In OVCA cell lines and primary specimens, BAD protein phosphorylation was associated with platinum resistance (n1⁄4 147, P < 0.0001) and also with overall patient survival (n1⁄4 134, P1⁄4 0.0007). Targeted modulation of BAD-phosphorylation levels influenced cisplatin sensitivity. A 47-gene BADpathway score was associated with in vitro phosphorylated BAD levels and with survival in 142 patients with advanced-stage (III/IV) serous OVCA. Integration of BAD-phosphorylation or BAD-pathway score with OVCA surgical cytoreductive status was significantly associated with overall survival by log-rank test (P 1⁄4 0.004 and P < 0.0001, respectively). Conclusion: The BAD apoptosis pathway influences OVCA chemosensitivity and overall survival, likely via modulation of BAD phosphorylation. The pathway has clinical relevance as a biomarker of therapeutic response, patient survival, and as a promising therapeutic target. Clin Cancer Res; 17(19); 6356–66. 2011

[1]  John Quackenbush,et al.  Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer , 2011, PloS one.

[2]  Zhou Wang,et al.  C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo , 2011, Cell Death and Disease.

[3]  Gen Sheng Wu,et al.  Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. , 2010, Biochemical and biophysical research communications.

[4]  H. Dressman,et al.  MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. , 2009, Gynecologic oncology.

[5]  C. Isidoro,et al.  Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop , 2008, Journal of cellular and molecular medicine.

[6]  F. Zunino,et al.  Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds , 2008, Molecular Cancer Therapeutics.

[7]  P. Bickford,et al.  Trophic factor induction of human umbilical cord blood cells in vitro and in vivo , 2007, Journal of neural engineering.

[8]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Maurice P H M Jansen,et al.  Molecular profiling of platinum resistant ovarian cancer , 2006, International journal of cancer.

[10]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[11]  Javed Khan,et al.  Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers , 2005, Clinical Cancer Research.

[12]  S. Korsmeyer,et al.  Oligomeric Bax is a component of the putative cytochrome c release channel MAC, mitochondrial apoptosis-induced channel. , 2005, Molecular biology of the cell.

[13]  Chung-Liang Ho,et al.  Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas , 2004, Clinical Cancer Research.

[14]  Li Yang,et al.  Calcineurin-mediated BAD Ser155 dephosphorylation in ammonia-induced apoptosis of cultured rat hippocampal neurons , 2004, Neuroscience Letters.

[15]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[16]  V. Baker.  Salvage therapy for recurrent epithelial ovarian cancer. , 2003, Hematology/oncology clinics of North America.

[17]  J. Krieglstein,et al.  Protein phosphatase type 2C dephosphorylates BAD , 2003, Neurochemistry International.

[18]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[19]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[20]  Mason R. Mackey,et al.  Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane , 2002, Cell.

[21]  J. Hayakawa,et al.  Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. , 2000, Cancer research.

[22]  H. Ruan,et al.  BAD Ser-155 Phosphorylation Regulates BAD/Bcl-XL Interaction and Cell Survival* , 2000, The Journal of Biological Chemistry.

[23]  T. Chittenden,et al.  Growth Factors Inactivate the Cell Death Promoter BAD by Phosphorylation of Its BH3 Domain on Ser155 * , 2000, The Journal of Biological Chemistry.

[24]  P. Cohen,et al.  Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. , 2000, The Biochemical journal.

[25]  R. Britten,et al.  Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. , 2000, Oncology reports.

[26]  J. Thigpen,et al.  Chemotherapy for ovarian cancer: current concepts. , 1999, Seminars in surgical oncology.

[27]  Jean-Claude Martinou,et al.  Bid-induced Conformational Change of Bax Is Responsible for Mitochondrial Cytochrome c Release during Apoptosis , 1999, The Journal of cell biology.

[28]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[29]  P B Laub,et al.  Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.

[30]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[31]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[32]  R. Ozols,et al.  Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. , 1994, Cancer research.

[33]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Sung-Chul Lim,et al.  A low level of nicotine-induced chemoresistance in a KB cell line. , 2008, Molecular medicine reports.

[35]  P. Munster,et al.  Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Cvijic,et al.  Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells. , 1998, Biochemical and Biophysical Research Communications - BBRC.

[37]  M. Piccart,et al.  New cytostatic drugs in ovarian cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .